The Filing Desk

Medifast

MED · NYSE · Consumer Staples · Financials, fiscal 2016 to 2025

MED · Last close · November 19, 2026
$11.98
Value Medifast yourself

Medifast's revenue fell 36.0% to $386 million in fiscal 2025. Its operating margin was −3.7%, down from 0.5% a year earlier. Free cash flow was $1 million, down 92.7%. It paid out $0 million in dividends and buybacks, 16% of free cash flow. The diluted share count rose 0.2%.

Medifast, Inc. Latest fiscal year ended December 31, 2025 10-K filed February 17, 2026 · 0001628280-26-008656 Updated
Revenue
$386M
36.0%
Operating margin
−3.7%
4.2 pts
Net income
−$19M
$2M a year earlier
Free cash flow
$1M
92.7%
Return on equity
−9.1%
10.2 pts
Market cap
$134M
Nov 19 close
P/E
—
Loss: no P/E

Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.

Charts show fiscal years, from the 10-K filings.

Income statement

Revenue and net income
US$ billions, fiscal years; net losses in red. Revenue on the left axis, net income on the right; zero is the same line on both.
Revenue (left axis)Net income (right axis)
Gross profit, R&D and operating income
US$ billions, fiscal years. Gross profit is revenue minus the cost of what was sold; research and development is one of the costs paid from it; what remains after all operating costs is operating income. Losses in red.
Gross profitResearch and developmentOperating income
Margins
Percent of revenue
GrossOperatingNetFree cash flow

From fiscal 2016 to 2024, earnings per share fell 22.7% a year and net income 23.4% a year, while buybacks cut the share count by 8%. Medifast then lost money in fiscal 2025.

Diluted earnings per share
US$ per share, fiscal years, restated for any stock splits; loss years in red.

Returns on capital

Return on capital and on equity
Percent. Return on capital is after-tax operating income over the money invested in the business (debt plus equity, minus cash); return on equity is net income over shareholders' equity. Both use the average of opening and closing balances.
Return on capitalReturn on equity

Balance sheet

Cash and debt
US$ billions, at each fiscal year end. Debt includes finance leases.
Cash and short-term investmentsDebt
Assets, liabilities and equity
US$ billions, at each fiscal year end. Assets equal liabilities plus equity; negative equity in red.
Total assetsTotal liabilitiesShareholders' equity
Debt and liquidity ratios
Times. Debt to equity, current assets over current liabilities, and net debt over EBITDA (a full year's).
Debt to equityCurrent ratioNet debt to EBITDA

Five years at a glance

Fiscal year endFY21FY22FY23FY24FY25
Cash and short-term investments11088149166166
Debt incl. finance leases—————
Net debt (negative means net cash)—————
Net debt to EBITDA—————
Debt to equity—————
Interest coverage—————
Current ratio1.8x1.6x2.4x3.3x4.7x
Quick ratio0.8x0.7x1.8x2.7x4.2x
US$ millions unless stated, at each fiscal year end. Net debt to EBITDA is debt minus cash, divided by operating income before depreciation and amortization: roughly how many years of those earnings the net debt equals. Debt to equity is debt as a multiple of shareholders' equity. Interest coverage is operating income divided by interest expense. The current ratio is current assets over current liabilities; the quick ratio leaves out inventory.

Cash flow

Cash from operations, capital spending and free cash flow
US$ billions, fiscal years. Free cash flow is cash from operations minus capital spending; negative years in red.
Cash from operationsCapital spendingFree cash flow
Stock-based compensation and buybacks
US$ billions, fiscal years. Shares paid to employees (stock-based compensation, a cost that uses no cash) against cash spent buying shares back. Buybacks that only match it leave the share count roughly where it was.
Stock-based compensationShare buybacks
Dividends and buybacks
US$ billions, cash paid in each fiscal year
DividendsShare buybacks
Diluted share count
Weighted-average diluted shares, millions

Projections

Project Medifast's revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.

Insider trades

Over the 12 months between November 20, 2025 and November 19, 2026, 3 insiders bought $1.7 million of Medifast shares on the open market, and 1 insider sold $226,300, all of it under trading plans set up in advance.

Buys and sells by month
US$ millions, open-market purchases (up) and sales (down) by officers, directors and 10% owners in each month.
BoughtSold
DateInsiderTradeSharesPriceValueFiling
Sep 29, 2026Daniel R ChardDirectorSold plan9,544$11.73$111,951Form 4
Sep 28, 2026Daniel R ChardDirectorSold plan9,545$11.98$114,349Form 4
Aug 26, 2026Parsa KiaiDirectorBought43,150$12.26$529,019Form 4
Aug 24, 2026Parsa KiaiDirectorBought4,329$12.00$51,948Form 4
Aug 20, 2026Parsa KiaiDirectorBought43,150$11.60$500,540Form 4
Aug 19, 2026Parsa KiaiDirectorBought29,337$11.66$342,069Form 4
May 11, 2026Scott SchlackmanDirectorBought2,500$12.53$31,325Form 4
May 8, 2026Scott SchlackmanDirectorBought2,500$12.65$31,625Form 4
Mar 20, 2026Daniel R ChardChairman & CEO, DirectorBought17,678$10.11$178,725Form 4
Open-market purchases and sales by officers, directors and 10% owners, from their Form 4 filings with the SEC: one row per person, day and filing, at the day's average price. Grants, option exercises and shares withheld for tax aren't counted. Insiders buy and sell for many reasons, such as taxes, spreading their savings or a plan set up months earlier, so a trade on its own says little about where a company is heading. For information only, not investment advice. Insider trades at all companies

Indicators

Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.

IndicatorFY23FY24FY25
Piotroski F-score———
Rule of 40−19.8%−41.0%−35.6%
Altman Z''9.328.5410.15
Accruals ratio−15.4%−7.5%−9.6%
Piotroski F-score: how many of nine simple tests of profitability, funding and efficiency the company passed in the year (Piotroski, 2000); 8 or 9 is strong, 0 to 2 weak. Rule of 40: revenue growth plus free cash flow margin; software investors treat 40% or more as the bar. Altman Z'': working capital, retained earnings, operating income and equity weighed against assets and liabilities (Altman, 1995); Altman puts above 2.6 in the safe zone and below 1.1 in the distress zone. Accruals ratio: net income minus cash from operations, over average total assets; lower means profit is backed by cash.

The nine F-score tests

TestFY23FY24FY25
Net income is positivePassPassFail
Cash from operations is positivePassPassPass
Return on assets roseFailFailFail
Cash from operations exceeds net incomePassPassPass
Debt fell relative to assets———
Current ratio rosePassPassPass
Share count didn't risePassFailFail
Gross margin rosePassPassFail
Revenue rose relative to assetsFailFailFail
F-score———
Companies that report no gross profit are scored on the other eight.

Compare

Put Medifast side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.

Similar companies

CompanyYearRevenue growthOperating marginFree cash flow marginReturn on capitalNet debt to EBITDAF-scoreCompare
MedifastFY25−36.0%−3.7%0.3%———
Black Rifle CoffeeFY251.7%−6.2%−3.4%−18.9%—4Compare
Beyond MeatFY25−15.6%−121.1%−57.1%−94.8%—3Compare
DDC EnterpriseFY250.3%−90.0%−101.3%−100.2%——Compare
Bridgford FoodsFY253.3%−8.1%−4.0%−12.4%—3Compare
Each company's latest fiscal year. Fiscal years end in different months, so the periods don't line up exactly. Free cash flow margin is free cash flow as a share of revenue. Net debt to EBITDA is explained under the balance sheet, and the F-score under Indicators.

10 years of figures

Fiscal yearFY16FY17FY18FY19FY20FY21FY22FY23FY24FY25
Income statement
Revenue2743025017149351,5261,5991,072602386
Revenue growth0.7%9.8%66.1%42.5%31.0%63.2%4.8%−32.9%−43.8%−36.0%
Gross profit2062283805376981,1281,140776445275
Research and development2223344554
Operating income274069911342161851263−14
Net income18285678103164144992−19
Diluted EPS (US$)1.492.294.626.438.6813.8912.739.100.19−1.70
Diluted shares (millions)12121212121211111111
Cash flow
Cash from operations2543618414594195148247
Capital expenditure3351063417686
Free cash flow2240567413960178141171
Dividends paid121523355364727310
Share buybacks003033556126400
Acquisitions0000000000
Stock-based compensation343471011878
Balance sheet at fiscal year end
Cash and short-term investments77991019317411088149166166
Debt incl. finance leases——————————
Total assets121146169195276398316310284248
Total liabilities253760901191961611087449
Shareholders' equity96107109105157202155202210199
Margins and ratios
Gross margin74.9%75.5%75.8%75.2%74.7%73.9%71.3%72.4%73.8%71.3%
Operating margin9.8%13.1%13.8%12.8%14.3%14.2%11.6%11.8%0.5%−3.7%
Net margin6.5%9.2%11.1%10.9%11.0%10.8%9.0%9.3%0.3%−4.8%
Free cash flow margin8.2%13.3%11.2%10.4%14.9%4.0%11.1%13.2%2.8%0.3%
Rule of 40 (growth + FCF margin)8.8%23.1%77.3%52.9%45.9%67.2%15.9%−19.8%−41.0%−35.6%
Return on capital——————————
Return on equity19.3%27.4%51.7%72.8%78.5%91.2%80.3%55.8%1.0%−9.1%
Return on assets15.0%20.8%35.4%42.8%43.7%48.6%40.2%31.8%0.7%−7.0%
Net debt to EBITDA——————————
US$ millions unless stated. Where a later 10-K restated a year, the latest filed figure is shown. Download all figures (CSV, US$ millions)
Source: Medifast's Form 10-K filings, from SEC EDGAR. For information only, not investment advice. The Filing Desk is not affiliated with Medifast.